Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas

Childs Nerv Syst. 2007 Sep;23(9):1041-6. doi: 10.1007/s00381-007-0409-3. Epub 2007 Jun 26.

Abstract

Objectives: The aim of this study was to verify whether intracystic injections of alpha-Interferon (IFN-alpha) in cystic craniopharyngiomas were able to reduce the tumor by activating the Fas apoptotic pathway.

Materials and methods: Twenty-one patients with cystic craniopharyngiomas treated at the Pediatric Oncology Institute (IOP/GRAACC) of Federal University of São Paulo were submitted to intracystic chemotherapy with IFN-alpha. The tumor sizes of all patients were monitored and the apoptotic factor soluble FasL (sFasL) concentration was determined by ELISA (enzyme-linked immunosorbent assay) in tumor fluid samples from eight patients.

Results: There was a complete reduction in 11 patients, a partial response in seven, and a minor response in three patients. The concentration of sFasL was increased in all the eight patients examined concomitantly with the tumor size reduction.

Conclusions: Our data demonstrated that the IFN-alpha was able to induce Fas-mediated apoptosis together with a reduction in the tumor size; such an observation may suggest the importance to investigate still unexplored mechanisms to be exploited in craniopharyngioma therapy.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Apoptosis / drug effects*
  • Child
  • Child, Preschool
  • Craniopharyngioma / pathology
  • Craniopharyngioma / therapy*
  • Drug Therapy / methods*
  • Enzyme-Linked Immunosorbent Assay / methods
  • Fas Ligand Protein / metabolism
  • Female
  • Humans
  • Immunologic Factors / therapeutic use*
  • Infant
  • Interferon-alpha / therapeutic use*
  • Magnetic Resonance Imaging / methods
  • Male
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / therapy*
  • Retrospective Studies
  • Tomography Scanners, X-Ray Computed

Substances

  • Fas Ligand Protein
  • Immunologic Factors
  • Interferon-alpha